Tags |
|
|
Links |
|
|
Digg It - Public Relations for High Rises
Public relations for high-rises is often difficult because many people
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
do not want to see giant buildings built in their city as a they call i
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
an eyesore. However beautiful high-rise buildings are hardly an eyeso
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
e, as they actually add to the community and make it look very importan
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
. Of course, those people who have lived there a long time do not want
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
to see more buildings in the area and they certainly do not want to se
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
high-rises.
In fact they will go out of their way to try to kill a pr
In fact they will go out of their way to try to kill a pr
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
ject at the planning commission stage whether or not they have good con
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
ern. Sometimes they say that the building may cast a shadow during cer
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
tain times of the day and that will make them feel like they're not get
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
ing enough sun.
Indeed this does sound rather silly, but actually envi
Indeed this does sound rather silly, but actually envi
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
onmental impact reports now do show the possible shadows during the day
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
ime and who and how they will affect things. If the shadow will cross
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
over in front of a hospital, school or high density housing sometimes t
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
at will be enough to kill the project.
High rises makes sense because
High rises makes sense because
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
hey build up rather than out and it is a better use of space however, m
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
ny people decry high-rises and that is why a good public relations spec
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
ialist is needed who has contacts in the area with all the local media.
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
You cannot keep everyone happy all the time and when it comes to high
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
ises some people are downright upset. Please consider all this in 2006
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggit.org.ua/article/33364/diggit-Public-Relations-for-High-Rises.html">Public Relations for High Rises</a>
BB link (for phorums):
[url=http://www.diggit.org.ua/article/33364/diggit-Public-Relations-for-High-Rises.html]Public Relations for High Rises[/url]
Related Articles:
CRM for the SME Market: More than Just Technology
Four Common Sense Tips for the Telephone Interview
What We Shop for: Customer Service
Bookmark it:
|